Cook MyoSite
Cook MyoSite, a subsidiary of Cook Group, has been advancing human muscle cell technology since 2002. Operating under ISO 9001:2015-certified quality standards, we specialize in primary human skeletal muscle-derived cells and fibro-adipogenic progenitors sourced from healthy donors and individuals with neuromuscular, metabolic, and rare disorders. Our offerings include custom cell procurement, specialized media formulations, and contract manufacturing services—supporting both academic research and clinical development in regenerative medicine. Beyond research tools, Cook MyoSite is pioneering autologous muscle-derived cell therapies. Our investigational product, iltamiocel, is currently in a Phase III clinical trial for fecal incontinence, demonstrating our commitment to translating cell-based science into real-world solutions. With expertise in GMP manufacturing, analytical testing, and tailored partnerships, we empower collaborators to accelerate innovation in musculoskeletal and neuromuscular health worldwide.
Industries
N/A
Nr. of Employees
small (1-50)
Cook MyoSite
100 Delta Drive Pittsburgh, PA 15238
Patents
Methods, substrates, and systems useful for cell seeding of medical grafts
2024-10-22 • US-12121631-B2
View Details
Methods, substrates, and systems useful for cell seeding of medical grafts
2024-10-22 • US-12121631-B2
View DetailsProducts
Primary human skeletal muscle-derived cells
Single-donor, characterized primary human skeletal muscle myoblast-like cells for fundamental and disease-specific research. Includes access to donor tissue from both healthy individuals and those with neuromuscular, metabolic, and rare disorders such as myotonic dystrophy, Guillain-Barre syndrome, Marfan syndrome, and Friedrich's ataxia, with robust metadata and clinical history available.
Human fibro-adipogenic progenitor cell preparations
Purified human primary fibro-adipogenic progenitor cells suitable for modeling muscle regeneration, fibrosis, adipogenesis, and disease across multiple donor backgrounds.
Custom muscle cell and media solutions
Tailored products and custom solutions, including procurement of specific donor tissue (healthy or disease), custom lot manufacturing, and unique media formulation.
Cell culture media and supplements
Basal, differentiation, cryopreservation, serum-free, and insulin-free media designed for primary muscle cell growth and differentiation.
Primary human skeletal muscle-derived cells
Single-donor, characterized primary human skeletal muscle myoblast-like cells for fundamental and disease-specific research. Includes access to donor tissue from both healthy individuals and those with neuromuscular, metabolic, and rare disorders such as myotonic dystrophy, Guillain-Barre syndrome, Marfan syndrome, and Friedrich's ataxia, with robust metadata and clinical history available.
Human fibro-adipogenic progenitor cell preparations
Purified human primary fibro-adipogenic progenitor cells suitable for modeling muscle regeneration, fibrosis, adipogenesis, and disease across multiple donor backgrounds.
Custom muscle cell and media solutions
Tailored products and custom solutions, including procurement of specific donor tissue (healthy or disease), custom lot manufacturing, and unique media formulation.
Cell culture media and supplements
Basal, differentiation, cryopreservation, serum-free, and insulin-free media designed for primary muscle cell growth and differentiation.
Expertise Areas
- Clinical trial management for cell-based therapies
- Cellular and regenerative medicine research
- GMP cell manufacturing
- Human skeletal muscle and progenitor cell biology
Key Technologies
- Primary human skeletal muscle cell isolation
- Autologous muscle-derived cell manufacturing
- Fibro-adipogenic progenitor cell production
- Custom cell culture media formulations
Key People
President
President
News & Updates
Laboratory research services manufactured under an ISO9001:2015 Certified Quality Management System.
Three separate RMAT designations awarded by the FDA for autologous muscle-derived cell therapies in stress urinary incontinence, fecal incontinence, and oropharyngeal dysphagia.
A compilation of peer-reviewed publications related to the muscle-derived cell therapy technology and its research applications.
Discussion of comparative advantages of primary human muscle cells over immortalized cell lines in research applications.
Expert opinions on the application and future of regenerative medicine in the field of urology.
Initiation of participant treatment in a Phase III trial evaluating safety and efficacy of autologous muscle-derived cells for chronic fecal incontinence in women with obstetric anal sphincter injury.
Laboratory research services manufactured under an ISO9001:2015 Certified Quality Management System.
Three separate RMAT designations awarded by the FDA for autologous muscle-derived cell therapies in stress urinary incontinence, fecal incontinence, and oropharyngeal dysphagia.
A compilation of peer-reviewed publications related to the muscle-derived cell therapy technology and its research applications.
Discussion of comparative advantages of primary human muscle cells over immortalized cell lines in research applications.
Expert opinions on the application and future of regenerative medicine in the field of urology.
Initiation of participant treatment in a Phase III trial evaluating safety and efficacy of autologous muscle-derived cells for chronic fecal incontinence in women with obstetric anal sphincter injury.